Ralliant (NYSE:RAL) Updates FY 2026 Earnings Guidance

Ralliant (NYSE:RAL) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 2.760-2.900 for the period, compared to the consensus EPS estimate of 2.650. The company issued revenue guidance of $2.3 billion-$2.3 billion, compared to the consensus revenue estimate of $2.2 billion. Ralliant also updated its Q3 2026 guidance to 0.720-0.780 EPS.

Wall Street Analyst Weigh In

RAL has been the topic of several recent analyst reports. Morgan Stanley lifted their price target on shares of Ralliant from $68.00 to $85.00 and gave the company an “overweight” rating in a report on Tuesday, June 23rd. Vertical Research lowered shares of Ralliant from a “buy” rating to a “hold” rating and set a $65.00 price objective for the company. in a report on Wednesday, May 27th. BMO Capital Markets started coverage on shares of Ralliant in a research report on Monday, July 20th. They issued a “market perform” rating and a $78.00 target price for the company. Truist Financial reaffirmed a “buy” rating and set a $82.00 target price (up from $68.00) on shares of Ralliant in a research note on Friday. Finally, Zacks Research upgraded shares of Ralliant from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, June 30th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Ralliant currently has a consensus rating of “Moderate Buy” and a consensus price target of $75.40.

Ralliant Stock Down 1.1%

Ralliant stock traded down $0.75 on Friday, hitting $66.25. 814,572 shares of the stock traded hands, compared to its average volume of 1,709,292. The company has a current ratio of 1.61, a quick ratio of 1.05 and a debt-to-equity ratio of 0.73. The firm has a market cap of $7.42 billion and a P/E ratio of -6.05. The business’s fifty day simple moving average is $67.12 and its 200 day simple moving average is $54.26. Ralliant has a 1 year low of $37.27 and a 1 year high of $75.41.

Ralliant (NYSE:RAL) last released its earnings results on Thursday, July 30th. The company reported $0.68 earnings per share for the quarter, topping analysts’ consensus estimates of $0.63 by $0.05. The firm had revenue of $567.80 million for the quarter. Ralliant had a negative net margin of 58.55% and a positive return on equity of 12.49%. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. As a group, sell-side analysts forecast that Ralliant will post 2.64 earnings per share for the current year.

Ralliant Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 23rd. Shareholders of record on Monday, June 8th were issued a $0.05 dividend. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date was Monday, June 8th. Ralliant’s dividend payout ratio is -1.83%.

Trending Headlines about Ralliant

Here are the key news stories impacting Ralliant this week:

• Positive Sentiment: Truist raised its price target to $82 from $68 while reaffirming a Buy rating, implying approximately 24% upside from the referenced share price. Benzinga analyst rating report
• Positive Sentiment: Ralliant beat second-quarter expectations: adjusted EPS was $0.68 versus the $0.63 consensus estimate, while revenue reached approximately $568 million, up 13% year over year. Adjusted EBITDA margins and net earnings margins also improved year over year. Ralliant second-quarter 2026 results
• Positive Sentiment: Management raised its full-year 2026 outlook. Adjusted EPS guidance increased to $2.76-$2.90, above the $2.65 analyst consensus, while revenue guidance of roughly $2.25-$2.30 billion is also above prior expectations. Ralliant 2026 forecast and productivity program
• Positive Sentiment: Third-quarter guidance also exceeded expectations, with EPS projected at $0.72-$0.78 versus a $0.68 consensus and revenue of $570-$590 million versus $556.4 million expected. The company additionally targets $50-$60 million of annualized productivity savings by 2028.
• Neutral Sentiment: Trading in RAL was temporarily paused under a limit-up/limit-down (“LULD”) volatility halt on July 30. The halt itself does not change the company’s earnings outlook but indicates elevated short-term trading volatility.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. UMB Bank n.a. raised its stake in Ralliant by 49.6% during the 4th quarter. UMB Bank n.a. now owns 983 shares of the company’s stock valued at $50,000 after buying an additional 326 shares during the last quarter. Maryland State Retirement & Pension System boosted its stake in shares of Ralliant by 1.5% in the 4th quarter. Maryland State Retirement & Pension System now owns 21,940 shares of the company’s stock worth $1,117,000 after buying an additional 329 shares during the last quarter. Xponance LLC grew its holdings in shares of Ralliant by 9.2% in the fourth quarter. Xponance LLC now owns 6,025 shares of the company’s stock worth $307,000 after acquiring an additional 509 shares during the period. Palisade Asset Management LLC bought a new stake in shares of Ralliant in the third quarter worth $26,000. Finally, BOKF NA purchased a new stake in Ralliant during the third quarter valued at $29,000.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.